Literature DB >> 11814626

Pharmacological characterization of the nociceptin receptor which mediates reduction of alcohol drinking in rats.

Roberto Ciccocioppo1, Carlo Polidori, Lorena Antonelli, Severo Salvadori, Remo Guerrini, Maurizio Massi.   

Abstract

Chronic intracerebroventricular (ICV) treatment with nociceptin/orphanin FQ (NC), the endogenous ligand for the opioid receptor-like 1 (ORL1) receptor, reduces ethanol intake in alcohol-preferring rats and abolishes the rewarding properties of ethanol in the place conditioning paradigm. To pharmacologically characterize the receptor involved, the present study evaluated the effect on ethanol drinking in genetically selected Marchigian Sardinian alcohol-preferring (msP) rats of ICV injections for 8 days of NC or of the NC analogs NC(1-17)NH(2), NC(1-13)NH(2), NC(1-12)NH(2) and [Nphe(1)]NC(1-13)NH(2). In vitro studies indicate that NC, NC(1-17)NH(2), NC(1-13)NH(2) and NC(1-12)NH(2) are agonists, while [Nphe(1)]NC(1-13)NH(2) is a selective antagonist at the ORL1 receptor. Freely feeding and drinking rats were offered 10% ethanol 30 min/day at the beginning of the dark phase of the light cycle. NC significantly attenuated ethanol intake at 500 or 1000 ng/rat (210 or 420 pmol/rat). NC(1-17)NH(2), markedly reduced ethanol intake, but its effect was statistically significant at 1000 (420 pmol/rat), not at 500 ng/rat (210 pmol/rat). After the end of treatment ethanol drinking promptly came back to baseline level. Ethanol consumption was also reduced by NC(1-13)NH(2); however, its effect was less potent and pronounced. NC(1-12)NH(2) did not modify ethanol intake at doses up to 4000 ng/rat (2339 pmol/rat). Water and food consumption were not modified. Treatment with [Nphe(1)]NC(1-13)NH(2), 66 or 99 microg/rat, did not modify ethanol intake; however, [Nphe(1)]NC(1-13)NH(2), 66 microg/rat, given just before 1000 ng/rat of NC(1-17)NH(2), abolished the effect of the agonist. The present results show that the 13 amino acid N-terminal sequence of NC is essential for the effect on ethanol intake and indicate that [Nphe(1)]NC(1-13)NH(2) acts as an antagonist to block the effect of NC. These findings provide further evidence that selective agonists at the ORL-1 receptor attenuate ethanol intake in alcohol-preferring rats and suggest that the NC/ORL1 system may represent an interesting target for treatment of alcohol abuse.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 11814626     DOI: 10.1016/s0196-9781(01)00587-3

Source DB:  PubMed          Journal:  Peptides        ISSN: 0196-9781            Impact factor:   3.750


  20 in total

1.  Participation of the nociceptin/orphanin FQ receptor in ethanol-mediated locomotor activation and ethanol intake in preweanling rats.

Authors:  Roberto Sebastián Miranda-Morales; Michael E Nizhnikov; Dustin H Waters; Norman E Spear
Journal:  Behav Brain Res       Date:  2013-02-21       Impact factor: 3.332

2.  Chronic treatment with novel brain-penetrating selective NOP receptor agonist MT-7716 reduces alcohol drinking and seeking in the rat.

Authors:  Roberto Ciccocioppo; Serena Stopponi; Daina Economidou; Makoto Kuriyama; Hiroshi Kinoshita; Markus Heilig; Marisa Roberto; Friedbert Weiss; Koji Teshima
Journal:  Neuropsychopharmacology       Date:  2014-06-27       Impact factor: 7.853

3.  NOP receptor antagonism reduces alcohol drinking in male and female rats through mechanisms involving the central amygdala and ventral tegmental area.

Authors:  Anna Maria Borruto; Yannick Fotio; Serena Stopponi; Gloria Brunori; Michele Petrella; Francesca Felicia Caputi; Patrizia Romualdi; Sanzio Candeletti; Rajesh Narendran; Linda M Rorick-Kehn; Massimo Ubaldi; Friedbert Weiss; Roberto Ciccocioppo
Journal:  Br J Pharmacol       Date:  2020-02-03       Impact factor: 8.739

4.  Nociceptin attenuates the escalation of oxycodone self-administration by normalizing CeA-GABA transmission in highly addicted rats.

Authors:  Marsida Kallupi; Lieselot L G Carrette; Jenni Kononoff; Leah C Solberg Woods; Abraham A Palmer; Paul Schweitzer; Olivier George; Giordano de Guglielmo
Journal:  Proc Natl Acad Sci U S A       Date:  2020-01-13       Impact factor: 11.205

5.  Nociceptin/orphanin FQ presynaptically decreases GABAergic transmission and blocks the ethanol-induced increase of GABA release in central amygdala.

Authors:  Marisa Roberto; George R Siggins
Journal:  Proc Natl Acad Sci U S A       Date:  2006-06-20       Impact factor: 11.205

6.  Nociceptin/orphanin FQ suppresses adaptive immune responses in vivo and at picomolar levels in vitro.

Authors:  Benito Anton; Phillipe Leff; Joseph J Meissler; Juan C Calva; Rodolfo Acevedo; Alberto Salazar; Maura Matus; Anabel Flores; Martin Martinez; Martin W Adler; John P Gaughan; Toby K Eisenstein
Journal:  J Neuroimmune Pharmacol       Date:  2010-02-02       Impact factor: 4.147

7.  A Paranigral VTA Nociceptin Circuit that Constrains Motivation for Reward.

Authors:  Kyle E Parker; Christian E Pedersen; Adrian M Gomez; Skylar M Spangler; Marie C Walicki; Shelley Y Feng; Sarah L Stewart; James M Otis; Ream Al-Hasani; Jordan G McCall; Kristina Sakers; Dionnet L Bhatti; Bryan A Copits; Robert W Gereau; Thomas Jhou; Thomas J Kash; Joseph D Dougherty; Garret D Stuber; Michael R Bruchas
Journal:  Cell       Date:  2019-07-25       Impact factor: 41.582

8.  A Novel and Selective Nociceptin Receptor (NOP) Agonist (1-(1-((cis)-4-isopropylcyclohexyl)piperidin-4-yl)-1H-indol-2-yl)methanol (AT-312) Decreases Acquisition of Ethanol-Induced Conditioned Place Preference in Mice.

Authors:  Nurulain T Zaveri; Paul V Marquez; Michael E Meyer; Willma E Polgar; Abdul Hamid; Kabirullah Lutfy
Journal:  Alcohol Clin Exp Res       Date:  2018-01-19       Impact factor: 3.455

9.  Buprenorphine reduces alcohol drinking through activation of the nociceptin/orphanin FQ-NOP receptor system.

Authors:  Roberto Ciccocioppo; Daina Economidou; Roberto Rimondini; Wolfgang Sommer; Maurizio Massi; Markus Heilig
Journal:  Biol Psychiatry       Date:  2006-03-14       Impact factor: 13.382

10.  Retrodialysis of N/OFQ into the nucleus accumbens shell blocks cocaine-induced increases in extracellular dopamine and locomotor activity.

Authors:  Jacqueline Vazquez-DeRose; Gregory Stauber; Taline V Khroyan; Xinmin Simon Xie; Nurulain T Zaveri; Lawrence Toll
Journal:  Eur J Pharmacol       Date:  2012-12-05       Impact factor: 4.432

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.